UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer

Cancer, 2019-05, Vol.125 (9), p.1459-1469

2019

Volltextzugriff (PDF)

Multisystem immune-related adverse events from dual agent immunotherapy use

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2635-2635

2023

Volltextzugriff (PDF)

Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21172-e21172

2022

Volltextzugriff (PDF)

Nivolumab in squamous cell carcinomas of the head and neck (SCCHN): A real-world outcome study in Ontario, Canada

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18017-e18017

2022

Volltextzugriff (PDF)

Incidence of venous thromboembolism in newly diagnosed glioblastoma multiforme and associated risk factors: A retrospective chart review

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e14040-e14040

2024

Volltextzugriff (PDF)

Oncologists and medical assistance in dying: Where do we stand?

Journal of clinical oncology, 2018-12, Vol.36 (34_suppl), p.64-64

2018

Volltextzugriff (PDF)

Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study

Journal of clinical oncology, 2016-10, Vol.34 (29), p.3537-3543

2016

Volltextzugriff (PDF)

Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e24126-e24126

2023

Volltextzugriff (PDF)

Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18694-e18694

2023

Volltextzugriff (PDF)

Can synthetic data accurately mimic oncology clinical trials?

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.1554-1554

2023

Volltextzugriff (PDF)

FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.460-460

2023

Volltextzugriff (PDF)

A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.692-692

2020

Volltextzugriff (PDF)

Retrospective analysis of ipilimumab-induced diarrhea and/or colitis: A single centre review

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e21064-e21064

2017

Volltextzugriff (PDF)

Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1532-1532

2022

Volltextzugriff (PDF)

Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.605-605

2022

Volltextzugriff (PDF)

Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.6629-6629

2019

Volltextzugriff (PDF)

Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.573-573

2023

Volltextzugriff (PDF)

Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.473-473

2020

Volltextzugriff (PDF)

Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.332-332

2022

Volltextzugriff (PDF)

SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

Clinical cancer research, 2023-06, Vol.29 (12), p.2220-2225

2023

Volltextzugriff (PDF)

SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9573-9573

2022

Volltextzugriff (PDF)

Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18628-e18628

2022

Volltextzugriff (PDF)

The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e23142-e23142

2019

Volltextzugriff (PDF)

C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.436-436

2018

Volltextzugriff (PDF)

Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR+ breast cancer in the TEAM trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.509-509

2023

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(119)

Publikationsform

Artikel
(121)
Dissertationen
(1)

Sprache

Englisch
(122)

Erscheinungsjahr

n.n

Thema

Oncology
(8)
Life Sciences & Biomedicine
(7)
Science & Technology
(7)
Humans
(6)
Female
(5)
Male
(5)
Aged
(4)
Urology & Nephrology
(4)
Middle Aged
(3)
Aged, 80 And Over
(2)
Carcinoma, Transitional Cell - Drug Therapy
(2)
Disease-Free Survival
(2)
Immunotherapy
(2)
Mutation
(2)
Prognosis
(2)
Prospective Studies
(2)
Retrospective Studies
(2)
Survival Analysis
(2)
Treatment Outcome
(2)
Adenomatous Polyposis Coli
(1)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer

Multisystem immune-related adverse events from dual agent immunotherapy use

Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada

Nivolumab in squamous cell carcinomas of the head and neck (SCCHN): A real-world outcome study in Ontario, Canada

Incidence of venous thromboembolism in newly diagnosed glioblastoma multiforme and associated risk factors: A retrospective chart review

Oncologists and medical assistance in dying: Where do we stand?

Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study

Evaluating response to interventions for vasomotor symptoms in patients with breast cancer: A patient-centered approach

Use of prophylactic and reactive feeding tubes in patients with esophageal cancer: A single-centre cohort study

Can synthetic data accurately mimic oncology clinical trials?

FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study

A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma

Retrospective analysis of ipilimumab-induced diarrhea and/or colitis: A single centre review

Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?

Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study)

Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada

Phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE trial

Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC)

Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative

SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma

Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative

The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement

C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy

Assessment of risk of overall and late distant recurrence by Breast Cancer Index in postmenopausal women with early-stage, HR+ breast cancer in the TEAM trial

Suchergebnisse filtern